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Abstract
Background: The transcription factor aryl hydrocarbon receptor (AhR) mediates the effects of a group of chemicals known
as dioxins, ubiquitously present in our environment. However, it is poorly known how the in vivo exposure to these
chemicals affects in humans the adaptive immune response. We therefore assessed the functional phenotype of T cells from
an individual who developed a severe cutaneous and systemic syndrome after having been exposed to an extremely high
dose of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).
Methodology/Principal Findings: T cells of the TCDD-exposed individual were studied for their capacity to produce
cytokines in response to polyclonal and superantigenic stimulation, and for the expression of chemokine receptors involved
in skin homing. The supernatants from T cells of the exposed individual contained a substantially increased amount of
interleukin (IL)-22 but not of IL-17A, interferon (IFN)-c or IL-10 when compared to nine healthy controls. In vitro experiments
confirmed a direct, AhR-dependent, enhancing effect of TCDD on IL-22 production by CD4+ T cells. The increased
production of IL-22 was not dependent on AhR occupancy by residual TCDD molecules, as demonstrated in competition
experiments with the specific AhR antagonist CH-223191. In contrast, it was due to an increased frequency of IL-22 single
producing cells accompanied by an increased percentage of cells expressing the skin-homing chemokine receptors CCR6
and CCR4, identified through a multiparameter flow cytometry approach. Of interest, the frequency of CD4+CD25
hiFoxP3+ T
regulatory cells was similar in the TCDD-exposed and healthy individuals.
Conclusions/Significance: This case strongly supports the contention that human exposure to persistent AhR ligands in
vivo induce a long-lasting effect on the human adaptive immune system and specifically polarizes CD4+ T cells to produce
IL-22 and not other T cell cytokines with no effect on T regulatory cells.
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Introduction
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is the most potent
member of a group of halogenated aromatic hydrocarbons,
generally known as dioxins [1]. Dioxins are produced when
organic material is burned in the presence of chlorine and are
therefore widely implicated in many industrial as well as natural
processes. Major sources of environmental dioxins include waste
incinerators and steel industry as well as the use of herbicide and
pesticide containing chlorophenols. Due to their high lipophilicity
and poor metabolism, dioxins accumulate in lipid-rich tissues of
animals and rapidly climb the food chain up to humans [2]. In
addition, dioxins are presents in cigarette smoke. As a conse-
quence, concentrations of dioxins are found in all humans, with
higher levels commonly identified in persons living in industrial-
ized countries.
TCDD, considered as the prototypical dioxin, has been shown
to have pleiotropic biological effects at low doses in multiple
animal species [3,4]. The majority of TCDD effects are mediated
via binding and activation of the intracellular aryl hydrocarbon
receptor (AhR), as demonstrated by the loss of responsiveness to
TCDD in AhR knockout mice [5]. The elevated toxicity of TCDD
is caused by its extremely high affinity for AhR and its long half-
life (5–10 years in humans [6]). Upon ligand binding AhR
undergoes a conformational change and translocates into the
nucleus, where it dimerizes with the AhR nuclear translocator
(ARNT) and regulates, by binding to xenobiotic response elements
(XRE), the expression of a variety of genes, including the
xenobiotic metabolizing enzyme CYP1A1 (cytochrome P450) [7].
In mice, AhR activation is reported to regulate T helper (Th) 17
and T regulatory (Treg) cell differentiation and to modulate
immune responses to experimental induced encephalomyelitis in a
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shown to be crucial for interleukin (IL)-22 expression [10] and a
regulatory mechanism for IL-22 production via a Notch-AhR axis
has been identified [11]. We [12] and others [13] have
demonstrated a role for AhR agonists, including TCDD, in
promoting the in vitro production of IL-22 but not of IL-17 by
human CD4 T cells. The possibility that in humans AhR
stimulation could participate to the in vitro differentiation of IL-
10-producing Treg cells has also been suggested [14].
IL-22 is a member of the IL-10 family of cytokines and signals
via a receptor consisting of IL-22R and IL-10R2 subunits. IL-22
does not serve the communication between immune cells since
cells of hematopoietic origin do not express IL-22R [15]. It mainly
acts on epithelial cells of the gastrointestinal tract and the skin,
where it promotes antimicrobial defense, protection against
damage and regeneration [16]. However, its role in chronic
inflammatory disorders may be either protective [17] or highly
pathogenetic [18,19]. T cells able to produce IL-22 in the absence
of IL-17 and interferon (IFN)-c, have been named Th22 cells and
are enriched in cells expressing the skin-homing chemokine
receptors CCR6, CCR4 and CCR10 while lacking CXCR3
[13,20]. Th22 cells have been identified in the skin of individuals
suffering of psoriasis and atopic dermatitis [21,22,23] and are
thought to be important in skin immunosurveillance and
immunopathology [13,20,21].
All the data on the effects of AhR ligands on human T cell
subsets have been so far generated in vitro and their relevance to in
vivo situations remains largely unknown. In this report, we
extensively characterize the long-term immunological modifica-
tions induced by TCDD in one of the two ever reported cases of a
human being who survived the in vivo exposure to an extremely
high dose of the pure compound [24]. Our data indicate for the
first time that in vivo exposure to TCDD induces a selective
increase in the frequency of T cells producing IL-22 but neither
IL-17, IL-10, nor IFN-c, which preferentially express skin-homing
chemokine receptors. These data strongly support the in vivo
existence in humans of Th22 cells that depend on AhR for their
expansion.
Materials and Methods
Patient
We obtained written approval from the patient to release peer-
reviewed scientific information about his case. Our patient had
been intoxicated by pure dioxin (TCDD) presumably in late 2004
at the age of 50. In early January 2005 he arrived under controlled
conditions at the Geneva University Hospital, Switzerland, where
we identified a TCDD concentration of 108,000 pg/g of lipid
weight in his blood serum [24]. Similar levels were identified by an
independent laboratory in a sample taken from the same patient in
mid-December 2004 [25]. This concentration was more than
50,000 times the averaged TCDD in the general population
(normal value: 10–20 pg/g of lipid weight) [26]. The patient was
suffering from a severe skin disease, the historically called
‘‘chloracne’’, consisting in what we call now ‘‘metabolizing
acquired dioxin-induced skin hamartomas’’ (MADISH) to de-
scribe his skin condition [27]. All the experiments shown in this
report were performed 4 years after the acute exposure to TCDD,
when the patient had a TCDD concentration of 19,000 pg/g of
lipid weight in his blood serum and no TCDD-related pathology
was anymore clinically apparent. Nine sex and age (52610 years)
matched healthy members of the laboratory served as controls.
CD4 and CD8 T cell frequencies in the peripheral blood of the
TCDD-exposed individual were within the range of healthy
controls (CD4+CD3+ T cells: 62.4% and 6167% of living
lymphocytes, respectively; CD3+CD8+ T cells: 25.7% and
1867% of living lymphocytes, respectively). Permission to perform
this investigation was granted by Comite ´ departemental de
me ´decine interne et me ´decine communaute `re des ho ˆpitaux
universitaires de Gene `ve. Written informed consent according to
the Helsinki declaration was obtained from each individual
involved in this study.
Reagents
Fetal calf serum (FCS), phorbol myristate acetate (PMA), b-
mercaptoethanol, staphylococcal enterotoxin B (SEB) and brefel-
din A were from Sigma Chemicals (St. Louis, MO); TCDD from
Cambridge Isotope Laboratories (Andover, MA); ionomycin from
Calbiochem (Merck KGaA, Darmstadt, Germany); RPMI 1640
medium, phosphate buffered saline (PBS), penicillin, streptomycin,
L-glutamin, nonessential amino acids, sodium pyruvate from Life
Technologies (Carlsbad, CA); human rIL-2 from Biogen (Zug,
Switzerland); anti-IL-22-PE from R&D (Minneapolis, MN); anti-
CD28 (CD28.2), anti-CD45RA-FITC, anti-CCR6-PercPCy5.5,
anti-CCR4-PECy7, anti-CXCR3-APC, anti-CD4-PE-Cy5, anti-
CD4-FITC, anti-CD4-APC-Cy7, anti-CD8-APC-Cy7 and anti-
CD3-FITC from BD (Franklin Lakes, NJ); anti-IL-17A-FITC,
anti-IL10-Alexa 488 and anti-IFN-c-PE-Cy7 from Biolegend (San
Diego, CA); anti-CD25-APC and anti-FoxP3-PE from eBioscience
(San Diego, CA); anti-CD3 (OKT3) Ab from ATCC (Manassas,
VA); CH-223191 from VWR (Dietikon, Switzerland).
Cell culture
Peripheral blood mononuclear cells (PBMC) were purified by
Ficoll-paque Plus (GE Healthcare, Pittsburgh, PA) gradient
centrifugation and frozen in liquid nitrogen until use or processed
immediately (experiment in Fig. 1A). The cells from the TCDD-
exposed individual were treated under the same experimental
conditions and in parallel to that of healthy individuals in all
experiments shown in this manuscript. PBMC were rested o/n in
RPMI 1640 medium supplemented with 10% FCS (complete
RPMI, cRPMI) as described [28] and then used in short term (up
to 24 h) or long term (7 d) cultures. In short term cultures PBMC
were activated for 4.5 h by PMA (50 ng/ml) and ionomycin
(1 mM) or for 24 hours in flat-bottom 96-well plates in presence of
coated anti-CD3 mAb (1 mg/ml) and soluble anti-CD28 mAb
(1 mg/ml). When intracellular cytokine determination was per-
formed, brefeldin A (2.5 mg/ml) was added after 1.5 and 3 hours
from the beginning of the activation, respectively. In long-term
activation experiments, PBMC were cultured at 1610
6 cells/ml in
24-well plates in cRPMI in the presence of soluble anti-CD3 Ab
(0.1 mg/ml) or SEB (0.2 mg/ml). Culture medium was supple-
mented with IL-23 (10 ng/ml) and IL-2 (20 U/ml) was added 48 h
after culture initiation. When used, TCDD (10 nM, unless
otherwise specified) and CH-223191 (3 mM) were added at the
beginning of the culture. At day 7 of culture, supernatants were
collected and frozen until cytokine determination and the cells
were harvested and activated for 4.5 h by PMA and ionomycin for
FACS analysis.
Flow cytometry and cytokine assays
Cell surface and intracellular staining were assessed by FACS
analysis using FACSCanto (BD) and data were analyzed by
FlowJo software 7.5 (Tree Star). For intracellular cytokine
determination, cells were stained with anti-CD4-PE-Cy5 or anti-
CD4-APC-Cy7 or anti-CD3-FITC mAbs, fixed and stained with
anti-IL-17A-FITC or anti-IL-10-Alexa 488, anti-IL-22-PE, anti-
IFN-c-PE-Cy7 and anti-IL-4-APC mAbs using BD Cytofix/
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determine the frequency of Treg cells, PBMC were stained with
anti-CD4-APC-Cy7, anti-CD45RA-FITC and anti-CD25-APC,
fixed and stained with anti-FoxP3-PE using eBioscience Foxp3
Fixation/Permeabilization buffer according to manufacturer’s
instruction. In chemokine receptor expression experiments,
PBMC were stained with anti-CD4-APC-Cy7, anti-CD45RA-
FITC, anti-CCR6-PercPCy5.5, anti-CCR10-PE, anti-CCR4-
PECy7 and anti-CXCR3-APC following by FACS analysis.
IFN-c, IL-22 and IL-10 were quantified in culture supernatants
at day 7 of culture by ELISA (R&D Systems or for IL-10 Sanquin,
Amsterdam, The Netherlands). IL-17 was quantified by ELISA
(R&D) or by Luminex xMAPTM Technology using multiplex
beads immunoassay (Fluorokine MAP Multiplex Human Cytokine
Panel, R&D).
Real-time quantitative PCR
Total RNA was extracted from resting PBMC using RNAesy
micro kit (Quiagen, Hilden, Germany) and cDNA synthesized
from 0.25 mg of total RNA using random hexamers and
Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA)
according to manufacturer’s instructions. SYBR Green assays
were performed on a SDS 7900 HT instrument (Applied
Biosystems). Each reaction was performed in triplicates. Raw Ct
values obtained with SDS 2.2.2 software (Applied Biosystems)
were analyzed and the more stable housekeeping genes TBP
(TATA-box-binding protein) and EEF1A1 (eukaryotic translation
elongation factor 1 alpha 1) selected for normalization. All
oligonucleotides were obtained from Quiagen: CYP1A1,
QT00012341; TBP1, QT00000721; EEF1A1, QT01669934.
Results and Discussion
CD4+ T cells characterized by the preferential production of
IL-22 in the absence of IL-17 and IFN-c have been recently
described by us and others in the peripheral blood of healthy
individuals [12,13,20]. These cells have been named Th22 cells.
Cells with similar characteristics have been detected in the skin of
individuals suffering of psoriasis and atopic dermatitis [21,22]. In
humans, AhR natural ligands such as the tryptophan photoprod-
uct 6-formylindolo[3,2-b]carbazole (FICZ) and b-naphthoflavone
as well as the synthetic ligand TCDD, have been shown to favor
the in vitro polarization of naı ¨ve CD4+ T cells toward IL-22-single
producing cells [12,13]. However, whether previous in vivo
exposure to an AhR-ligand in humans could favor the preferential
outgrowth of a particular cell subset, thus affecting the adaptive T
cell response, is unknown at present. To test this hypothesis, we
determined the capacity of PBMC of a person surviving the
exposure to an extremely high dose of the stable AhR ligand
TCDD to produce cell subset discriminating cytokines upon CD3-
crosslinking. When compared to those of 9 healthy individuals, the
PBMC of the TCDD-exposed individual produced at base-line 3-
fold higher levels of IL-22 but similar levels of IL-17A, IFN-c and
IL-10 (Figure 1A). Similarly, PBMC of the TCDD-intoxicated
individual secreted higher amounts of IL-22 but not of IL-17A and
Figure 1. In vivo TCDD-exposure increases IL-22 but does not concomitantly affect IL-17A, IFN-c and IL-10 production by PBMC.
Cytokine levels were assessed at d 7 in supernatants of PBMC activated by CD3-crosslinking (A) or by Staphylococcal Enterotoxin B (SEB) (B). IL-2
(20 U/ml) was added 48h after culture initiation. Individual data for a single TCDD-exposed individual (full symbols) and 9 (CD3-crosslinking) or 2 (SEB
stimulation) different healthy individuals (empty symbols) are shown.
doi:10.1371/journal.pone.0018741.g001
Figure 2. The levels of Treg cells are comparable in the
peripheral blood of TCDD-exposed and healthy individuals.
Surface staining of ex-vivo isolated PBMC from the TCDD-exposed and a
representative healthy individual of five tested. Plots are gated on CD4+
T cells, numbers in plots indicate the percentage of CD25
hiFoxP3+ Treg
cells (A) or that of CD45RA+FoxP3
lo resting and CD45RA-FoxP3
hi
activated Treg cells (B) in the CD4+ T cell fraction.
doi:10.1371/journal.pone.0018741.g002
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Enterotoxin B (SEB) (Figure 1B). SEB is a superantigen able to
specifically activate a subset of T cells expressing the T cell
receptors Vb3, Vb12, Vb13.2, Vb14, Vb15, Vb17 and Vb20
chains [29]. Thus, persistent TCDD-exposure in vivo does not
favor in humans the outgrowth of IL-17 producing Th17 cells, as
observed in mice [9,10,30,31], nor of IL-10 producing Tr1 cells, as
observed in vitro in humans [8,9,14]. In contrast, it selectively
favors the production of IL-22, induced in response to both
mitogenic and superantigenic stimulation.
To further address the possible expansion of Treg cells upon
exposure to TCDD as documented in mice [8,9], we assessed the
frequency of CD4+ T cells simultaneously expressing high levels of
the IL-2 receptor subunit CD25 and the Treg-specific transcrip-
tion factor FoxP3 in resting conditions [32]. We observed
comparable levels of CD25
hiFoxP3+ cells in the CD4+ T cell
fraction of ex-vivo isolated PBMC from the TCDD-exposed and 5
healthy individuals (2.49% and 2.2861.13% of CD4 T cells,
respectively) (Figure 2A). Similarly, no difference were identified
in the frequency of both resting (CD45RA+FoxP3
lo: 0.94% and
1.6560.92% of CD4 T cells, respectively) and activated
(CD45RA-FoxP3
hi: 0.8% and 0.7460.25% of CD4 T cells,
respectively) Treg cells, as defined by the expression of the
phosphatase CD45RA and the transcription factor FoxP3
(Figure 2B) [32]. Thus, the frequency and subset composition
of T cells with regulatory function was unaffected by TCDD
exposure, although TCDD levels were still 10,000 times above
normal values.
We next tested whether in vitro TCDD could modulate the
production of IL-22, IL-17A and IFN-c by PBMC activated upon
CD3-crosslinking. We found that TCDD dose-dependently
increased further the production of IL-22 in the TCDD-exposed
individual and, as expected, boosted IL-22 production in controls.
This increase was specific as far as IFN-c was not affected while
IL-17A production decreased in the presence of TCDD
(Figure 3A). Thus, exposure to TCDD in our patient did not
alter the ability of his lymphocytes to respond to TCDD
stimulation and did not result in lymphocyte exhaustion.
Together, these data corroborate and expand previous observa-
tions demonstrating a direct ability of TCDD to modulate the
production of IL-22 cytokine in short-term culture in vitro [12].
TCDD is thought to form a long-lived and stable complex with
AhR [7]. Thus, the higher amount of IL-22 produced by PBMC of
the TCDD-exposed individual in the absence of exogenously
added TCDD could result from the persistent action of the ligand
on a stable number of cells. Alternatively, it could be explained by
an increased frequency of IL-22-producing cells previously primed
in vivo under the influence of TCDD. To discriminate between
these two hypotheses, we cultured the PBMC in the presence of
the high-affinity AhR-antagonist CH-223191. If residual TCDD
was binding AhR in the TCDD-exposed individual, the AhR
antagonist would reduce the amount of IL-22 produced upon T
cell activation by displacing at least in part the bound TCDD,
otherwise no effects would be observed. The presence of the AhR
antagonist CH-223191 in the culture in the absence of TCDD did
not decrease the basal level of IL-22 produced by the TCDD-
exposed subject to the one observed in healthy individuals
(Figure 3B). However, the specific AhR antagonist completely
reversed the enhanced IL-22 and decreased IL-17A production
observed when exogenous TCCD was added to the cultures in
both the TCDD-exposed and healthy individuals (Figure 3B). To
confirm these findings, we assessed the mRNA levels of the AhR-
target gene CYP1A1, which is readily up-regulated by TCDD
ligation [7]. In agreement with the lack of inhibition by CH-
223191 in basal conditions, which suggests no occupancy of
TCDD binding sequences, no differences were observed in the
Figure 3. In vitro TCDD enhances IL-22 and down-regulates IL-17A production by PBMC in an AhR dependent manner. (A) PBMC were
activated by CD3-crosslinking in the presence or absence of TCDD and the specific AhR inhibitor CH-223191. Cytokine levels were assessed in the
supernatants harvested at d 7. Dose-dependent responses to TCDD in a single TCDD-exposed individual (full symbols) and one healthy individual
(empty symbols). (B) Culture conditions as in A. Cytokine determination in a single TCDD-exposed individual (full symbols) and 2 healthy individuals
(empty symbols) (C) mRNA levels of CYP1A1 quantified by real-time PCR of resting PBMC from a single TCDD-exposed (full symbols) and five healthy
individual (empty symbols). Expression levels have been normalized against the geometric mean of two house-keeping genes (EEF1A1 and TBP).
doi:10.1371/journal.pone.0018741.g003
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(full symbols) and healthy individuals (empty symbols) upon activation by PMA/Ionomycin for 4.5 h (n=5) or CD3/CD28 crosslinking for 24 h (n=9).
(B, C, D) Representative FACS plots of cells activated by PMA/Ionomycin from the TCDD-exposed and a control individual (upper right panel in B)
after gating on the forward and side scatter of viable PBMC (B, C) or on CD4+ cells (D). Numbers in plots indicate the percentage of cells in each
quadrant.
doi:10.1371/journal.pone.0018741.g004
Figure 5. Increased frequency of CD4+ memory T cells expressing the skin-homing receptors CCR6+ and CCR4+ in an individual
exposed in vivo to high levels of TCDD. Surface chemokine receptor expression on CD4+CD45RA- memory T cells from ex-vivo isolated PBMC in
a TCDD-exposed (full symbols) or 5 healthy individuals (empty symbols). (A) Mean 6 SD of cells expressing CCR6, CCR4, CXCR3 and CCR10. (B)
Percentage of cells expressing various combinations of CCR6, CCR4, CXCR3 and CCR10. Data from the 5 healthy individuals are expressed as box
plots. Box plots were automatically generated using GraphPad Prism version 4.00 for Windows (GraphPad Software). The box represents values
between 25th and 75th percentile with a line at the median (50th percentile). The whiskers extend above and below the box to show the highest and
the lowest values. 6, 4, 3 and 10 in panel B denote CCR6, CCR4, CXCR3 and CCR10, respectively.
doi:10.1371/journal.pone.0018741.g005
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exposed and control individuals (Figure 3C). These data
demonstrate the involvement of AhR in mediating dioxin effects
and, most importantly, suggest that the AhR receptor was not
anymore occupied in the TCDD-exposed individual at the time of
our investigation. Thus, the increased production of IL-22 could
be explained by an increased frequency of cells producing IL-22,
which accumulated with time while responding to novel antigenic
challenges under the polarizing effect exerted by TCDD. To test
this hypothesis we assessed the frequency of ex vivo-detectable IL-
22-secreting CD4+ cells in PBMC from the TCDD-exposed and
healthy individuals. We observed that the frequency of CD4+ cells
producing IL-22 was at least 3-fold higher in the TCDD-exposed
individual compared to controls. By contrast, the frequency of cells
producing IL-17A, IL-10 and IFN-c was similar (Figure 4A). The
increase in IL-22 producing cells was reproducible in short term
cultures across a variety of activation stimuli, which included
TCR-dependent (CD3 and CD28 cross-linking) and TCR-
independent (PMA and ionomycin) signaling (Figure 4A and
B). In the CD4+ compartment, IL-22 is mainly produced by
CD3+ T cells and to a minor extent by CD3- cells including
lymphoid tissue inducer (LTi) cells [33]. In the TCDD exposed
individual, all IL-22 producing cells were CD3+, thus indicating
that the source of IL-22 was CD4+ T cells (Figure 4B and C). Of
interest, multiparameter flow cytometry analysis revealed that the
majority of the IL-22+ cells in the TCDD-exposed individual did
not concomitantly produce IL-17A, IL-4, IFN-c (Figure 4B) and
IL-10 (Figure 4D). Altogether, these data strongly indicate that in
vivo exposure to TCDD favors the expansion of CD4+ T cells
having the functional properties of Th22 cells.
Since the exposure to dioxin resulted in severe skin manifesta-
tions, we tested whether the pattern of chemokine receptors
associated with skin homing expressed in CD4+ T cells was skewed
in the TCDD-exposed individual [34,35,36,37,38]. We found that
the frequency of CCR6+ and CCR4+ cells in the memory CD4 T
cell compartment was higher in the TCDD-exposed individual
than in controls, while the frequency of CXCR3+ cells was lower
(Figure 5A). This is remarkable, since Th22 cells were shown to
be enriched in CD4+ T cells expressing CCR6, CCR4 and
CCR10 in absence of CXCR3 [13,20]. A detailed multipara-
metric analysis performed at a single cell level, revealed that in the
TCDD-exposed individual there was a substantial three-fold
increase in the frequency of CD4+ memory T cells with the
CCR6+CCR4+CXCR3-CCR10- phenotype and a modest in-
crease in the CCR6+CCR4-CXCR3-CCR10- subset when
compared to healthy controls (Figure 5B). No differences were
identified in the CCR6- compartment, thus stressing the specificity
of our finding. It is noteworthy that we did not observe a
concomitant preferential expression of CCR10 in the TCDD-
exposed individual as observed by others in Th22 cells [13,20].
This may reflect a specific characteristic of T cell producing IL-22
under the influence of TCDD.
It is tempting to speculate that Th22 may have contributed to
some extent to the pathogenesis of the dioxin induced skin lesions
[27]. Th22 cells have been shown to be involved in skin disease
such as psoriasis and atopic dermatitis [21,22,23] which molecular
pathology is very different from the dioxin-induced skin lesions,
historically called ‘‘chloracne’’ and now defined as ‘‘metabolizing
acquired dioxin induced skin hamartomas’’ which primarily
involve sebaceous glands [27]. Further studies are needed to
analyze the putative effect, if any, of IL-22 in sebaceous gland
pathology. However, It is also possible that the skewed pattern of
chemokine receptor expression in the TCDD-exposed individual
was only the consequence of the expansion of Th22 cells taking
place with time.
In conclusion, we present here strong evidence indicating that
prolonged exposure in vivo to high dose of TCDD induces a
profound, long-lasting, perturbation of the adaptive immune
system and specifically polarizes CD4+ T cells to produce IL-22
but not other T cell cytokines in an AhR-dependent manner. The
best model explaining our findings suggest that antigenic exposure
taking place under the influence of TCDD polarizes T cells to the
Th22 subset. While historically relevant environmental disasters
[39,40,41] caused people exposure to a mix of toxic agent
including TCDD, the case here discussed represents a unique
opportunity for investigating the effect of pure dioxin on human T
cells. TCDD is one of the major environmental pollutants, present
in food and in cigarette smoke. While current doses are largely
below those observed in the index case, our observation helps to
better understand the effect of dioxin on the human immune
system.
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